LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Sunesis Pharmaceuticals, Inc. (“Sunesis” or the “Company”) (Nasdaq: SNSS) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at firstname.lastname@example.org.
On May 2, 2017, Sunesis announced that it will withdraw its European Marketing Authorization Application for vosaroxin, its proposed treatment for relapsed/refractory AML. Sunesis stated that its decision followed recent interactions with the European Medicine Agency’s Committee for Medicinal Products for Human Use, in which it learned that the committee was likely to adopt a negative opinion in its evaluation of the product.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.